ICLR
Earnings in 1 day · May 4, 2026 · After close
Signal
Mixed11
Price
1
Move-4.63%Selling pressure
Volume
1
Volume0.5× avgNormal activity
Technical
1
RSIRSI 56Momentum positive
PRICE
Prev Close
118.33
Open
119.66
Day Range112.13 – 120.49
112.13
120.49
52W Range66.57 – 211.00
66.57
211.00
32% of range
VOLUME & SIZE
Avg Volume
2.0M
FUNDAMENTALS
P/E Ratio
15.2x
EPS (TTM)
Div Yield
No dividend
Beta
1.19
Market-like
Quick Read
TrendInsufficient MA data
Momentum
NEUTRAL
rev -2% · 27% gross margin
Valuation
FAIR
P/E 15x vs ~20x sector
Health
STRONG
CR 1.1 · FCF $12.87/sh
Bullish
Key MetricsTTM
Market Cap$8.62B
Revenue TTM$8.10B
Net Income TTM$599.48M
Free Cash Flow$995.80M
Gross Margin26.9%
Net Margin7.4%
Operating Margin12.2%
Return on Equity6.3%
Return on Assets3.6%
Debt / Equity0.38
Current Ratio1.06
EPS TTM$7.75

Intelligence analysis not yet available for this stock. Full AI-powered analysis may be available on the intelligence page.

Health Radar
1 strong2 watch3 concern
38/100
Liquidity
1.06Watch
Leverage
0.38Strong
Coverage
4.9xWatch
ROE
6.3%Concern
ROIC
6.9%Concern
Cash
$539MConcern
ANALYST COVERAGE27 analysts
BUY
+12.5%upside to target
L $100.00
Med $127.00consensus
H $222.00
Buy
1763%
Hold
933%
Sell
14%
17 Buy (63%)9 Hold (33%)1 Sell (4%)
Full report →
Stock Health
Composite Score
3 of 4 signals bullish
9/10
Technicals
RSI RangeRSI 56 — Bullish momentum
Fundamentals
Last EarningsBeat estimates
Analyst ConsensusBuy
LiquidityCurrent Ratio 1.06
~

1 signal unavailable — limited data for this stock

Upcoming Events
EEarnings ReportMay 4, 2026
Tomorrow
DEx-Dividend DateJul 31, 2026
In 89 days
PDividend PaymentOct 28, 2026
In 178 days
Technicals
Technical SetupBEARISH
Technicals →

Trend

DowntrendDeath Cross · 50D trails 200D by 20.3%

-11.8% vs SMA 50 · -29.7% vs SMA 200

Momentum

RSI56.0
Positive momentum, not extended
MACD-6.24
Below zero — bearish pulse · expanding
Market Position
Price Levels
52W High
$211.0+87.0%
EMA 200
$147.9+31.1%
EMA 50
$122.6+8.6%
Current
$112.8
52W Low
$66.57-41.0%
52-Week RangeMid-range
$66.5732th %ile$211.0
Earnings & Analysts

ANALYST ESTIMATES

Consensus of 12 analysts
Analyst revisions:EPS↑ Revised UpRevenue↑ Revised Up

Analyst consensus estimates · Actuals replace estimates as reported

YearRevenue Est.Rev GthEPS Est.EPS GthRangeAnalysts
FY2025
$8.1B
$8.0B$8.1B
$12.97
±3%
High12
FY2026(current)
$7.9B
$7.5B$8.0B
-2.2%$11.87-8.5%
±11%
High11
FY2027
$8.2B
$7.8B$8.4B
+3.6%$12.78+7.7%
±13%
High8
Range confidence:Tight (high)ModerateWide (low)
🔥Beat 4 consecutive quarters
Earnings HistoryICLR
Last 8Q
-0.3%avg beat
Beat 7 of 8 quartersMissed 1 Estimates falling
+1%
Q1'24
+2%
Q2'24
+2%
Q3'24
-13%
Q4'24
+1%
Q1'25
+3%
Q2'25
+2%
Q3'25
+1%
Q4'25
Beat
Miss
Estimate
Deeper color = bigger beat/miss
Analyst Activity
All ratings →
Neutral — mixed activity
90d30
BMO CapitalMarket Perform → Outperform
Mar 26
UPGRADE
JefferiesHold → Buy
Feb 23
UPGRADE
Cowen & Co.Hold → Buy
Feb 18
UPGRADE
JefferiesBuy → Hold
Sep 9
DOWNGRADE
BarclaysEqual-Weight → Overweight
Jan 13
UPGRADE
Bank of America Sec…Buy
Nov 9
UPGRADE
Financials

INSTITUTIONAL OWNERSHIP

1
GREENHAVEN ASSOCIATES INC
2.0M
2
Trinity Street Asset Management LLP
1.2M
3
THRIVENT FINANCIAL FOR LUTHERANS
622K
4
Stephens Investment Management Group LLC
599K
5
abrdn plc
399K
6
River Road Asset Management, LLC
370K
7
HGK ASSET MANAGEMENT INC
319K
8
Fisher Funds Management LTD
174K
News & Activity

ICLR News

20 articles · 4h ago

About

icon is a global provider of outsourced development services to the pharmaceutical, biotechnology and medical device industries. we specialise in the strategic development, management and analysis of programmes that support clinical development - from compound selection to phase i-iv clinical studies. in a highly fragmented industry, we are one of a small group of organisations with the capability and expertise to conduct clinical trials and development projects on either a local or global basis. we have the operational flexibility to provide development services on a stand-alone basis or as part of an integrated “full service” solution. we are also an 'end-to-end'​ pharmacovigilance service provider and this includes post marketing surveillance activities too.

Industry
Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
CEO
Stephen Cutler
Country
Ireland
Gary CurtisSenior Vice President of Global Clinical Pharmacology
Simon HolmesPresident of Corporate Investments & Partnerships
David GreenVice President of Marketing